Schering Aktiengesellschaft

Henry Laurent

Rudolf Wiechert

Helmut Hofmeister

Klaus Annen

Dieter Bittler

Klaus Nickisch

Karl Petzoldt

Walter Elger

Hans Wendt

Sybille Beier

Peter Esperling

Wolfgang Losert

Yukishige Nishino

Gerald Kirsch

Hermann Steinbeck

Joachim-Friedrich Kapp

Michael Topert

Klaus Prezewowsky

Jorge Casals-Stenzel

James R Bull

Paul E Schulze

Kunhard Pollow

Andreas Huth

Rolf Bohlmann

Gerhard Sauer

Gunter Neef

Helmut Wachtel

Herbert H Schneider

David A Henderson

Ralph Lipp

Klaus Kieslich

Friedmund Neumann

Petra Rach

Ekkehard Winterfeldt

Walter Klose

Rudolf Weichert

Michael Toepert

Wolfgang Froehlich

Peter Klaus Mengel

Martin Haberey

Eckhard Ottow

Gregor Haffer

Ulrich Eder

Alfred Weber

Ekkehard Schillinger

Mario Kennecke

Thomas Brumby

Helmut Dahl

Guenter Neef

Jutta Riedl

Jurgen Ruppert

Ralph Rohde

Rolf Krattenmacher

Paul-Eberhard Schulze

Robert C Nickolson

Daryl Faulds

Harald Dinter

Hans-Jorg Vidic

Johannes-Wilhelm Tack

Ernst Schottle

Kurt Hamp

Ulrich Tauber

Clemens Gunther

Bernhard Manz

Joachim F Kapp

Yukeshige Nishino

Hans-Joerg Grill

Klaus Nickish

Helmut Schroeder

Russell I Thomson

Hans J Grill

Hans-Peter Lorenz

Ulf Tilstamm

Hans J Zentel

Ulrike Ullmann

Andreas Kramer

Klaus Engel

Klaus Mengel

Karl-Heinz Kolb

3-Oxyiminopregnane-21-carbolactones of formula I,

Oxyiminopregnancarbolactones

This invention relates to (R)-(-)-methylphenyloxazolidinone derivatives, a process for their production and their use as pharmaceutical agents.

Chiral methylphenyloxazolidinones

Chiral phenyldihydrofuranones as PDE-IV inhibitors

Pharmaceutical preparations for the local treatment of inflammations are claimed herein, characterized in that they contain as the active ingredient one or two compounds of general Formula I ##STR1## wherein X is an oxygen atom or a methylene group,

Oxazolidinone compounds and pharmaceutical preparation containing them

Agent for transdermal administration that contains gestodene esters

Administration of oxazolidinone and pyrolidinone compounds for the

Cephalostatin analogues

Glucocorticoids

A 14.alpha.,17.alpha.-bridged estratriene of formula I ##STR1## wherein (a) OR.sup.3 is in .alpha.-position

14.alpha., 17.alpha.-ethano-16.alpha.-hydroxy-estratrienes

14.alpha., 16.alpha.-ethanoand 14.alpha., 16.alpha.-etheno-estratrienes

Process for the production of 3-deoxy-4-ene steroids

##STR1## New 14.alpha.,17.alpha.-ethano-estratrienes of general formula (I) wherein R.sup.1 is a hydrogen atom, an alkyl or acyl group with 1 to 12 carbon atoms, R.sup.2 is a hydrogen atom or a methyl group, R.sup.3 is a hydrogen atom or an acyl group with 1 to 12 carbon atoms and (a) is either (II) or (III), where R.sup.4 is an alkyl residue in the .alpha. or .beta. position with 1 to 8 carbon atoms or an .alpha.,.beta.-alkenyl residue which may contain several double bonds or an .alpha.,.beta.-alkinyl residue, both with 2 to 8 carbon atoms, are described. Also described is a process for producing them. These new compounds have a marked oestrogenic activity.

14.alpha.,17.alpha.-ethanoestratrienes

Androstane derivatives of the general Formula I ##STR1## in which R.sub.1 represents a hydrogen atom or a methyl group,

Androstane derivatives

Known pregnane derivatives are prepared by esterification of know androstane derivatives to give new esters of Formula III ##STR1## wherein  in each case symbolizes a single bond or a double bond,

Process for the preparation of pregnane derivatives

Estrane and androstane derivatives of formula I ##STR1## wherein X is bromine, iodine, triphenyltin or trialkyltin of 1 to 6 carbon atoms per alkyl radical,

Estrane and androstane derivatives, process for producing them and

Growing community of inventors

Berlin, Germany

Henry Laurent